What is Palmiges?
Based on the provided evidence, "Palmiges" appears to refer to Palmitoylethanolamide (PEA), an endogenous fatty acid amide that functions as a lipid mediator with anti-inflammatory and analgesic properties 1, 2, 3.
Mechanism of Action
PEA works through several pathways:
- Activates peroxisome proliferator-activated receptor alpha (PPAR-α), which inhibits nuclear factor kappa B (NF-κB) activity, reducing pro-inflammatory cytokine production 2
- Synergizes with the endogenous cannabinoid system to modulate neurotransmission by enhancing endocannabinoid function 2
- Regulates glial cells and mast cells, reducing both local and central inflammation while protecting and promoting neuronal regeneration 2
Indications Beyond Fracture Compression
PEA has no established indication for fracture compression—the evidence provided does not support this use. Instead, PEA is used for various chronic pain conditions:
Primary Indications:
- Neuropathic pain syndromes: diabetic neuropathy, chemotherapy-induced peripheral neuropathy 4
- Nerve compression syndromes: sciatic pain (number needed to treat = 1.5 for 50% pain reduction after 3 weeks), carpal tunnel syndrome 5
- Chronic low back pain with sciatica: significant NRS reduction from 5.12±0.79 to 1.65±0.66 over 4 weeks 1
- Other conditions: osteoarthritis, failed back surgery syndrome, dental pain, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia 4
Clinical Evidence:
A 2023 meta-analysis of 11 double-blind RCTs (774 patients) demonstrated PEA reduced pain scores with a standard mean difference of 1.68 (95% CI 1.05-2.31, p<0.00001) 3. The DN4 neuropathic pain scores also decreased significantly across most descriptors 1.
Side Effects
PEA demonstrates exceptional safety with virtually no significant adverse effects reported:
- No serious side effects documented across more than 30 clinical trials involving ~6,000 patients since the 1970s 5
- No drug-drug interactions reported 5, 4
- Well-tolerated with no major adverse events in systematic reviews 3
- No relevant adverse events in recent clinical trials 1
Safety Profile Rationale:
PEA's remarkable safety profile is attributed to it being both an endogenous modulator naturally produced in the body and a compound found in common foods like eggs and milk 4. This endogenous nature explains the absence of typical pharmaceutical side effects.
Clinical Considerations
PEA is particularly valuable as an adjunctive or alternative therapy when:
- Patients are intolerant to conventional pharmacological treatments (NSAIDs, opioids) 1
- Long-term pain management is required without the risk of dependence 2
- Pregabalin has proven ineffective (as it has been shown ineffective in sciatic pain in double-blind trials) 5
Onset of action: Pain reduction can occur as early as 3 days after supplementation, with continued improvement over weeks 1.
Duration of treatment: Most clinical trials evaluated PEA over 3-4 week periods, though it can be used for chronic conditions given its safety profile 1, 5.